Kezar Life Sciences, Inc. (KZR) - Shares of the clinical-stage biotechnology company soared nearly 80% after closing bell. The company's lead drug candidate is KZR-616, a selective inhibitor of immunoproteasome that plays a crucial role in the immune system.
from RTT - Earnings https://ift.tt/3dxrgR9
via IFTTT
No comments:
Post a Comment